BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12424937)

  • 1. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
    Schüll B; Scheithauer W
    Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
    Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
    Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.
    Khouri C; Guiu B; Cercueil JP; Chauffert B; Ladoire S; Ghiringhelli F
    Anticancer Drugs; 2010 Jul; 21(6):656-61. PubMed ID: 20216061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
    Cascinu S; Graziano F; Ferraù F; Catalano V; Massacesi C; Santini D; Silva RR; Barni S; Zaniboni A; Battelli N; Siena S; Giordani P; Mari D; Baldelli AM; Antognoli S; Maisano R; Priolo D; Pessi MA; Tonini G; Rota S; Labianca R
    Ann Oncol; 2002 May; 13(5):716-20. PubMed ID: 12075739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
    Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
    Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
    Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
    Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
    Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Valencak J; Weinländer G; Hejna M; Haider K; Kwasny W; Depisch D
    J Clin Oncol; 1999 Mar; 17(3):902-6. PubMed ID: 10071282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
    Seitz JF; Bennouna J; Paillot B; Gamelin E; François E; Conroy T; Raoul JL; Becouarn Y; Bertheault-Cvitkovic F; Ychou M; Nasca S; Fandi A; Barthelemy P; Douillard JY
    Ann Oncol; 2002 Jul; 13(7):1072-9. PubMed ID: 12176786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
    Schmid KE; Kornek GV; Schüll B; Raderer M; Lenauer A; Depisch D; Lang F; Scheithauer W
    Onkologie; 2003 Jun; 26(3):255-8. PubMed ID: 12845210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
    Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N; Kosmas C; Vadiaka M; Koufos C
    BMC Cancer; 2002; 2():2. PubMed ID: 11860608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.